Tissue Destruction and Healing in Celiac Disease
ConditionCeliac Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of Chicago
About this trial
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
Eligibility criteria
Qualifiers
Age 18 to 75 years old
Diagnosis of Celiac disease for at least 12 months by intestinal biopsy
Follow a strict gluten-free diet for at least the 12 consecutive months
Age 18 to 75 years old
Disqualifiers
Diagnosis of any severe complication of celiac disease
Diagnosis of other chronic, active GI disease
Selective IgA deficiency
Severe reaction to gluten exposure
Trial design
Treatments tested in this trial
- Gluten containing snack bar
Treatment groups
220 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of Chicago
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Mayo Clinic
Collaborator
California Institute of Technology
Collaborator
Source ClinicalTrials.gov